Clinical trials
Overweight trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
84 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 2 |
| 2014 | 3 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 11 |
| 2024 | 16 |
| 2025 | 7 |
| 2026 | 17 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Recruiting | 16 |
| Unknown status | 13 |
| Not yet recruiting | 9 |
| Active, not recruiting | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking University | 5 |
| Capital Medical University | 4 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 4 |
| Beijing Sport University | 3 |
| The First Affiliated Hospital of Xiamen University | 3 |
| Universiti Putra Malaysia | 3 |
| Children's Hospital of Fudan University | 2 |
| Hong Kong Baptist University | 2 |
| Huazhong University of Science and Technology | 2 |
| Peking University Third Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Overweight | 84 |
| Obesity | 75 |
| Metabolic Syndrome | 5 |
| Weight Loss | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Diabetes, Gestational | 3 |
| Polycystic Ovary Syndrome | 3 |
| Prediabetic State | 3 |
| Atrial Fibrillation | 2 |
| Cognitive Dysfunction | 2 |
Trials
Showing 1 to 25 of 84. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.